

1 **People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after**
2 **dual COVID-19 vaccination, and strong third dose responses**

3
4 Hope R. Lapointe^{1*}, Francis Mwimanzi^{2*}, Peter K. Cheung^{1,2}, Yuroou Sang², Fatima Yaseen³, Gisele
5 Umviligihozo², Rebecca Kalikawe², Sarah Speckmaier¹, Nadia Moran-Garcia¹, Sneha Datwani², Maggie
6 C. Duncan^{1,2}, Olga Agafitei², Siobhan Ennis², Landon Young⁴, Hesham Ali⁵, Bruce Ganase⁶, F. Harrison
7 Omondi^{1,2}, Winnie Dong¹, Junine Toy², Paul Sereda², Laura Burns⁸, Cecilia T. Costiniuk⁹, Curtis
8 Cooper^{10,11}, Aslam H. Anis^{12,13,14}, Victor Leung^{4,8,15}, Daniel Holmes^{8,15}, Mari L. DeMarco^{8,15}, Janet
9 Simons^{8,15}, Malcolm Hedgcock¹⁶, Natalie Prystajek^{15,17}, Christopher F. Lowe^{4,8,15}, Ralph Pantophlet^{2,3},
10 Marc G. Romney^{4,8,15}, Rolando Barrios^{1,12}, Silvia Guillemi^{1,18}, Chanson J. Brumme^{1,7}, Julio S.G.
11 Montaner^{1,7}, Mark Hull^{1,7}, Marianne Harris^{1,18}, Masahiro Niikura², Mark A. Brockman^{1,2,3#}, Zabrina L.
12 Brumme^{1,2#}

13
14 * and # denote equal contribution

15
16 ¹ British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada;

17 ² Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;

18 ³ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada;

19 ⁴ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada;

20 ⁵ John Ruedy Clinic, St. Paul's Hospital, Vancouver, Canada

21 ⁶ AIDS Research Program, St. Paul's Hospital, Vancouver, Canada

22 ⁷ Department of Medicine, University of British Columbia, Vancouver, Canada;

23 ⁸ Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada;

24 ⁹ Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and
25 Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

26 ¹⁰ Department of Medicine, University of Ottawa, Ottawa, Canada

27 ¹¹ Ottawa Hospital Research Institute, Ottawa, Canada

28 ¹² School of Population and Public Health, University of British Columbia, Vancouver, Canada

29 ¹³ CIHR Canadian HIV Trials Network, University of British Columbia, Vancouver, Canada

30 ¹⁴ Centre for Health Evaluation and Outcome Sciences, Vancouver, Canada

31 ¹⁵ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,
32 Canada

33 ¹⁶ Spectrum Health, Vancouver, Canada

34 ¹⁷ British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada

35 ¹⁸ Department of Family Practice, Faculty of Medicine, University of British Columbia, Canada

36

37 **Running title:** COVID19 vaccine in people with HIV

38

39 **Corresponding Author Contact Information:**

40 Zabrina L. Brumme, Ph.D.

41 Professor, Faculty of Health Sciences, Simon Fraser University

42 8888 University Drive, Burnaby, BC, Canada, V5A 1S6

43 Tel: 778 782-8872; Fax: 778-782-5927; email: zbrumme@sfu.ca; zbrumme@bccfe.ca

44 **ABSTRACT**

45

46 **Background:** Longer-term humoral responses to two-dose COVID-19 vaccines remain incompletely
47 characterized in people living with HIV (PLWH), as do initial responses to a third dose.

48 **Methods:** We measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain,
49 ACE2 displacement and viral neutralization against wild-type and Omicron strains up to six months
50 following two-dose vaccination, and one month following the third dose, in 99 PLWH receiving
51 suppressive antiretroviral therapy, and 152 controls.

52 **Results:** Though humoral responses naturally decline following two-dose vaccination, we found no
53 evidence of lower antibody concentrations nor faster rates of antibody decline in PLWH compared to
54 controls after accounting for sociodemographic, health and vaccine-related factors. We also found no
55 evidence of poorer viral neutralization in PLWH after two doses, nor evidence that a low nadir CD4+ T-
56 cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-
57 dose levels, though anti-Omicron responses were consistently weaker than against wild-type.
58 Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-
59 1273 third dose was the strongest consistent correlate of higher post-third-dose responses.

60 **Conclusion:** PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after
61 two- and three-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in
62 light of Omicron.

63

64 **KEYWORDS:** HIV, COVID-19, vaccines, immune response, humoral, antibodies, neutralization, third
65 dose

66 INTRODUCTION

67 As people living with HIV (PLWH) may be at increased risk of severe COVID-19 due to
68 immunosuppression, higher rates of multi-morbidity and/or social determinants of health [1-4], COVID-
69 19 vaccination is expected to benefit this group. Two-dose COVID-19 vaccination protects against severe
70 disease [5-7], but impaired responses have been observed in certain immunocompromised groups [8-12].
71 While antiretroviral therapy can reverse HIV-induced immune dysfunction to a large extent [13-16],
72 persistent HIV-related immunopathology can nevertheless blunt vaccine responses [17-19], prompting
73 initial concern that PLWH may respond sub-optimally to COVID-19 immunization. Data from clinical
74 trials [20, 21] and real-world studies however [22-27], including from our group [28], described strong
75 initial immune responses to two-dose COVID-19 vaccination in PLWH with controlled HIV loads on
76 therapy and preserved CD4+ T-cell counts [20-24, 28], though weaker responses have been observed in
77 PLWH who are not receiving therapy or who have CD4+ T-cell counts <200 cells/mm³ [22, 25-27].

78 Vaccine-induced antibody responses decline over time, which can increase the risk of post-
79 vaccination SARS-CoV-2 infection [29-31], particularly with the more transmissible Omicron variant [32-
80 36]. Though immune response durability following two-dose COVID-19 vaccination has been examined
81 among PLWH participants of the ChAdOx1 clinical trial [37], few real-world studies have investigated
82 this. Furthermore, no studies to our knowledge have investigated immune responses in PLWH to third
83 vaccine doses, despite their widespread recommendation to maintain protection [38-40]. Here, we extend
84 our previous report [28] to characterize binding and neutralizing antibody responses up to six months
85 following two-dose COVID-19 vaccination, as well as one month following the third dose, in 99 PLWH
86 and 152 controls without HIV. We assess responses to both wild-type and Omicron SARS-CoV-2
87 variants.

88 **METHODS**

89 **Participants.** We previously recruited 99 adult PLWH and 152 controls without HIV, the latter
90 predominantly health care workers, in British Columbia (BC), Canada [28]. Serum and plasma (collected
91 in either ethylenediaminetetraacetic acid [EDTA] or anticoagulant citrate dextrose [ACD]) were collected
92 before vaccination; one month after the first dose; one, three and six months after the second dose; and
93 one month following the third dose. Specimens were processed same-day and frozen at -80°C until
94 analysis. Here we report on the post-second- and third-dose time points.

95
96 **Ethics approval.** All participants provided written informed consent. This study was approved by the
97 University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics
98 Boards.

99
100 **Data sources.** Sociodemographic, health and COVID-19 vaccine data were collected by self-report and
101 confirmed through medical records where available. We assigned a score of 1 for each of 11 chronic
102 conditions: hypertension; diabetes; asthma; obesity (body mass index ≥ 30 kg/m²); chronic diseases of
103 lung, liver, kidney, heart or blood; cancer; and immunosuppression due to chronic conditions or
104 medication. For PLWH, a recent CD4⁺ T-cell count < 200 cells/mm³ constituted immunosuppression.

105
106 **Binding antibody assays.** We measured total binding antibodies against SARS-CoV-2 nucleocapsid (N)
107 and spike (S) receptor binding domain (RBD) in serum using the Elecsys Anti-SARS-CoV-2 and Anti-
108 SARS-CoV-2 S assays, respectively, on a Cobas e601 module analyzer (Roche Diagnostics). Post-
109 infection, both assays should be positive, whereas post-vaccination only the S assay should be positive.
110 Both tests are electro-chemiluminescence sandwich immunoassays, and report results in arbitrary

111 Units/mL. For the S assay, the manufacturer indicates that these arbitrary Unit (U) values can be
112 considered equivalent to WHO-defined international binding antibody units [41]. For the S assay, sera
113 were tested undiluted, with samples above the upper limit of quantification (ULOQ) re-tested at 1:100
114 dilution, allowing a measurement range of 0.4-25,000 U/mL. Anti-RBD binding IgG concentrations in
115 serum were quantified using the V-plex SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso Scale
116 Diagnostics), which features wild-type and Omicron antigens, on a Meso QuickPlex SQ120 instrument.
117 Sera were diluted 1:10000, with results reported in arbitrary Units/mL.

118

119 ***ACE2 displacement assay.*** We assessed the ability of serum antibodies to block the RBD-ACE2 receptor
120 interaction by competition ELISA (Panel 22 V-plex SARS-CoV-2 [ACE2]; Meso Scale Diagnostics) on a
121 Meso QuickPlex SQ120 instrument. Sera were diluted 1:40 and results reported as % ACE2 displacement.

122

123 ***Live virus neutralization.*** Neutralizing activity in plasma was examined in live SARS-CoV-2 assays using
124 isolate USA-WA1/2020 (BEI Resources) and a local Omicron BA.1 isolate (GISAID Accession #
125 EPI_ISL_9805779) on VeroE6-TMPRSS2 (JCRB-1819) target cells. Viral stock was adjusted to 50
126 TCID₅₀/200 µl in Dulbecco's Modified Eagle Medium in the presence of serial 2-fold plasma dilutions
127 (from 1/20 to 1/2560), incubated at 4°C for 1 hour and added to target cells in 96-well plates in triplicate.
128 Cultures were maintained at 37°C with 5% CO₂ and the appearance of viral cytopathic effect (CPE) was
129 recorded three days post-infection. Neutralizing activity is reported as the reciprocal of the highest plasma
130 dilution able to prevent CPE in all triplicate wells. Samples exhibiting partial or no neutralization at 1/20
131 dilution were assigned a reciprocal dilution of 10, defined as below the limit of quantification (BLOQ).

132

133 ***Statistical analysis.*** Continuous variables were compared using the Mann-Whitney U-test (unpaired data)
134 or Wilcoxon test (paired data). Relationships between continuous variables were assessed using
135 Spearman's correlation. Multiple linear regression was used to investigate the relationship between
136 sociodemographic, health and vaccine variables and immune outcomes, except for neutralization at 6
137 months post-second dose, where multiple logistic regression was used due to the high proportion of results
138 BLOQ. Variables included HIV infection (controls as reference group), age (per year), sex at birth (female
139 as reference), ethnicity (non-white as reference), number of chronic conditions (per additional), interval
140 between first and second doses (per day), sampling date after vaccination (per day), dual ChAdOx1 as the
141 initial regimen (mRNA or mixed [ChAdOx1/mRNA] regimen as the combined reference group), and prior
142 COVID-19 (COVID-19-naive as reference). Plasma neutralization models also corrected for the
143 anticoagulant (ACD as reference). Post-third-dose analyses also corrected for the third dose mRNA
144 vaccine brand (BNT162b2 as reference) and the interval between second and third doses (per day). All
145 tests were two-tailed, with $p < 0.05$ considered statistically significant. Analyses were conducted using
146 Prism v9.2.0 (GraphPad).
147

148 RESULTS

149 *Cohort characteristics*

150 All PLWH were receiving antiretroviral therapy and had suppressed plasma HIV loads (**Table 1**).

151 Recent CD4+ T-cell counts, measured a median 44 days before enrolment, were a median 715 cells/mm³

152 (Interquartile Range [IQR] 545-943; range 130-1800), where only two participants had values <200

153 cells/mm³. Nadir CD4+ T-cell counts were a median 280 cells/mm³ (IQR 123-490; range <10-1010). The

154 99 PLWH and 152 controls were broadly similar in age, but the PLWH group included a greater

155 proportion of males and of white ethnicity. PLWH and controls had similar numbers of chronic health

156 conditions (45% and 33%, respectively, had at least one condition). At study entry, 8% of PLWH and

157 10% of controls had anti-N antibodies, indicating prior SARS-CoV-2 infection. An additional 31

158 participants (18 PLWH; 13 controls) experienced post-vaccination SARS-CoV-2 infections, 26 of which

159 occurred during the Omicron wave. More PLWH received dual ChAdOx1 vaccines for their first two

160 doses (8%) compared to <1% of controls. On average, the interval between first and second doses was

161 longer for controls (median 89 days versus 58 for PLWH). In British Columbia (BC), third doses began to

162 be offered in October 2021 to priority populations, including PLWH who had one or more of: age \geq 65

163 years, prior AIDS-defining illness, prior CD4 count <200 cells/mm³ or prior CD4 fraction \leq 15%, any

164 plasma HIV load >50 copies/mL in 2021, or perinatally-acquired HIV. The majority of PLWH in BC met

165 at least one of these criteria. By January 2022, all remaining adults in BC aged \geq 18 years were eligible for

166 a third dose 6 months after their second dose. At the time of writing, 80% of PLWH participants and 88%

167 of controls had received a third dose, on average 6.3 months following their second dose. All third doses

168 were mRNA vaccines, and more PLWH (70%) received mRNA-1273 compared to controls (59%). Third

169 mRNA-1273 doses also differed by risk group: 100 mcg was recommended for adults aged \geq 70 years and

170 PLWH who met any priority criterion, whereas the standard booster dose of 50 mcg was recommended for
171 all other adults.

172

173 ***Binding antibody responses after second and third doses***

174 One month following two-dose vaccination, anti-RBD antibody concentrations were a median 3.9
175 [IQR 3.7-4.1] \log_{10} U/mL in PLWH compared to a median of 4.0 [IQR 3.8-4.2] \log_{10} in controls (p=0.04,
176 **Figure 1A**). By three months following the second dose, antibody concentrations had declined in both
177 groups, to a median of 3.4 [IQR 3.2-3.6] \log_{10} U/mL in PLWH compared to a median of 3.6 [IQR 3.4-3.8]
178 \log_{10} U/mL in controls (p=0.0001). These differences however did not remain significant in multivariable
179 analyses controlling for sociodemographic, health- and vaccine-related variables (p-values for HIV
180 infection p=0.83 and p=0.088, respectively, **Supplemental Table 1**). Rather, a greater number of chronic
181 conditions and dual ChAdOx1 vaccination were independently associated with lower antibody
182 concentrations at both time points, while a longer dose interval was associated with higher antibody
183 concentrations (all p<0.05), regardless of HIV status. Older age was also significantly correlated with
184 lower antibody concentrations one month post-second dose (p=0.0053), and was marginally significant at
185 three months (p=0.055). Participants with prior COVID-19 (where post-vaccination infections are shown
186 as red dots on **Figure 1A**) displayed modestly higher responses at one- and three-months post-second
187 dose, though this did not remain significant after multivariable correction.

188 By six months after the second dose, antibody concentrations had declined to a median of 3.1
189 [IQR 2.9-3.3] \log_{10} U/mL in PLWH versus a median 3.2 [IQR 3.0-3.4] \log_{10} U/mL in controls (p=0.0021,
190 **Figure 1A**), though this difference did not remain significant after multivariable correction (p=0.64;
191 **Table 2**). Rather, dual ChAdOx1 vaccination was the strongest correlate of weaker responses at this time
192 point, being associated with a nearly a \log_{10} adjusted lower antibody concentration (p<0.0001), regardless

193 of HIV status. Age was no longer a correlate of weaker responses at the six-month time point ($p=0.99$),
194 while a longer time between vaccination and sampling was associated with marginally higher antibody
195 concentrations ($p=0.0067$). This is likely driven by 13 control participants aged ≥ 70 years who did not
196 contribute samples to this time point due to receipt of third doses less than six months after the second
197 dose, and 25 participants aged ≥ 65 years who contributed this sample early due to imminently scheduled
198 third doses as per the age-based rollout in BC. Prior COVID-19 was associated with superior antibody
199 concentrations at the six-month time point (**Figure 1A** and **Table 2**), though this is influenced by 11
200 participants with recent infections.

201 We next assessed temporal reductions in antibody concentrations after two vaccine doses (**Figure**
202 **1B**). Assuming exponential decay, and restricting the analysis to COVID-19-naïve participants with a
203 complete post-second-dose longitudinal series with no values above the assay upper limit of quantification
204 (ULOQ), we estimated antibody half-lives to be a median of 53 [IQR 47-70] days in PLWH versus a
205 median of 59 [IQR 51-75] days in controls ($p=0.023$, **Figure 1C**). This difference however did not remain
206 significant after multivariable correction ($p=0.63$; **Table 2**).

207 A third vaccine dose boosted antibody concentrations to an average of 0.4-0.5 \log_{10} U/mL higher
208 than peak post-second dose levels (within-group $p<0.0001$ for both PLWH and controls), to a median of
209 4.3 [IQR 4.2 to >ULOQ] \log_{10} U/mL in PLWH and 4.4 [IQR 4.2 to >ULOQ] \log_{10} U/mL in controls
210 (between-group $p=0.83$), values that were comparable to those in participants with prior COVID-19
211 (**Figure 1A**). Multivariable analyses were not performed as nearly 50% of values were >ULOQ.

212 Consistent with our previous observations at one and three months post-second vaccine dose [28],
213 we observed no significant relationship between most recent or nadir CD4+ T-cell count and antibody
214 concentrations either six months after the second dose or one month following the third dose in PLWH

215 (Supplementary Figure 1). We also observed no significant relationship between these CD4 parameters
216 and antibody half-life after the second dose (Spearman $\rho \leq 0.16$, $p \geq 0.3$; not shown).

217

218 *Viral neutralization after second and third doses*

219 One month after the second vaccine dose, SARS-CoV-2 neutralization was achieved at a median
220 reciprocal plasma dilution of 160 (IQR 40-320) in PLWH compared to a median of 80 (IQR 40-160) in
221 controls (Mann-Whitney $p=0.06$, **Figure 2A**). By three months post-second dose this activity declined to
222 40 [IQR 20-80] in both PLWH and controls ($p=0.23$). Multivariable analyses identified older age, a higher
223 number of chronic conditions and dual ChAdOx1 vaccination as significant independent correlates of
224 poorer neutralization one month post-second dose (all $p < 0.05$), with negative effects of dual ChAdOx1
225 vaccination ($p=0.0032$) and to a lesser extent age ($p=0.059$) persisting at three months (**Supplemental**
226 **Table 1**). Prior COVID-19 was associated with higher neutralization at both of these time points
227 following multivariable correction (both $p \leq 0.0002$).

228 By six months post-second dose, neutralization had declined to below the limit of quantification
229 (BLOQ) in 52% of COVID-19-naive participants, to a median reciprocal dilution of 20 [IQR BLOQ-40]
230 in PLWH and a median BLOQ [IQR BLOQ-20] in controls ($p=0.07$, **Figure 2A**). Due to the large
231 proportion of BLOQ values, we applied multivariable logistic regression with neutralization as a binary
232 variable, and identified only prior COVID-19 as a biological correlate of neutralization at this time point
233 ($p=0.0037$; **Supplemental Table 2**). This however is influenced by 11 participants with recent infections.

234 A third COVID-19 vaccine dose boosted neutralization to an average of fourfold higher than peak
235 post-second-dose levels (within-group $p < 0.0001$ for PLWH and controls; **Figure 2A**). In fact,
236 neutralization activities in PLWH (median reciprocal dilution of 640 [IQR 160-1280]) exceeded those of
237 controls (median of 320 [160-320]; Mann-Whitney $p=0.0006$) at this time point, though this did not

238 remain significant following multivariable adjustment ($p=0.15$; **Supplemental Table 3**). Rather, having
239 received mRNA-1273 as a third dose was the strongest independent correlate of better neutralization
240 ($p=0.0009$). Prior COVID-19 was associated with better neutralization, though it is difficult to disentangle
241 infection- from vaccine-induced responses due to a number of recent infections (red circles in **Figure 2A**).

242 We observed no significant relationship between most recent CD4+ T-cell count and neutralization
243 at either six months post-second dose nor at one month post-third dose in COVID-19 naive PLWH; nor
244 any relationship between nadir CD4+ T-cell count and neutralization at six months post-second dose
245 (**Supplemental Figure 1**). An inverse relationship between nadir CD4+ T-cell count and neutralization
246 one month after the third dose however was found (Spearman $\rho = -0.28$; $p=0.04$).

247

248 *Humoral responses against Omicron following two and three vaccine doses*

249 To estimate the extent to which a third dose boosts protection against the now-dominant Omicron
250 variant, we compared peak responses against wild-type and Omicron variants one month following the
251 second and third doses. To avoid confounding by infection-induced immunity, we restricted this analysis
252 to COVID-19-naive individuals. For both PLWH and controls, serum IgG concentrations capable of
253 binding Omicron RBD were on average $\sim 0.6 \log_{10}$ U/mL lower than those capable of binding wild-type
254 RBD at both time points (all within-group comparisons $p < 0.0001$; **Figure 3A**). Nevertheless, the third
255 dose significantly boosted anti-Omicron IgG concentrations to an average of 0.3-0.5 \log_{10} U/mL higher
256 than those observed after two doses in both groups (within-group comparisons $p < 0.0001$). One month
257 post-second dose, anti-Omicron IgG concentrations were a median 4.12 [IQR 3.93-4.35] \log_{10} U/mL in
258 PLWH and a median of 4.28 [IQR 3.97-4.56] \log_{10} U/mL in controls ($p=0.04$), but after three doses, these
259 responses reached equivalence, with medians of 4.51 [IQR 4.26-4.93] \log_{10} U/mL in PLWH versus 4.56
260 [IQR 4.24-4.74] \log_{10} U/mL in controls ($p=0.63$). In fact, a multivariable analysis of Omicron-specific

261 IgG concentrations after three doses identified HIV infection as being associated with an adjusted 0.36
262 \log_{10} U/mL *higher* anti-Omicron IgG concentrations ($p=0.0017$; **Table 3**). Having received mRNA-1273
263 for the third dose, as well as longer interval between second and third doses, were also associated with
264 higher anti-Omicron IgG responses (both $p<0.05$); male sex was associated with lower responses
265 ($p=0.032$).

266 We also assessed the ability of plasma to block the RBD-ACE2 interaction, which estimates
267 potential viral neutralization [42]. This activity was significantly weaker against Omicron compared to
268 wild-type for both groups at both time points (all within-group comparisons $p<0.0001$; **Figure 3B**), where
269 the discrepancy was most pronounced after two doses (*e.g.* median activities against wild-type and
270 Omicron in PLWH were 97% versus 42%, respectively, at this time). The third dose nevertheless
271 universally boosted anti-Omicron responses to above second-dose levels (all within-group comparisons
272 $p\leq 0.0009$), with median anti-Omicron activity in PLWH rising from 42% after two doses to 57% after
273 three ($p=0.0009$). Anti-Omicron ACE2 % displacement activities were comparable between groups at
274 both time points: one month after the second dose these were a median 42% [IQR 27-61] in PLWH
275 compared to 39% [IQR 20-62] in controls ($p=0.55$), rising to a median 57% [IQR 33-77] in PLWH
276 compared to 62% [IQR 44-77] in controls one month after the third dose ($p=0.37$). In multivariable
277 analyses, male sex was the only independent (negative) correlate of anti-Omicron ACE2 displacement
278 activity after three doses ($p=0.031$, **Table 3**). After three doses, we observed a weak inverse relationship
279 between nadir CD4+ T-cell count and anti-Omicron ACE2 % displacement (Spearman $\rho = -0.3$; $p=0.02$),
280 but no relationship between other CD4+ T-cell count measures and anti-Omicron responses
281 (**Supplemental Figure 1**).

282 Finally, we assessed plasma neutralization against live wild-type and Omicron viruses at one
283 month following the second and third doses in a subset of COVID-19-naive participants (**Figure 4**). While

284 neutralization against Omicron was significantly weaker compared to wild-type at both time points in both
285 PLWH and controls (all within-group comparisons $p < 0.0001$), the third dose nevertheless significantly
286 boosted anti-Omicron neutralization above second dose levels (both within-group comparisons $p < 0.0001$).
287 One month after the second dose, both PLWH and controls neutralized Omicron at a median reciprocal
288 dilution of 20 [IQR BLOQ - 40] ($p = 0.71$). One month after the third dose, anti-Omicron neutralization
289 activity increased to a median reciprocal dilution of 80 [IQR 40-160] in PLWH compared to a median 40
290 [IQR 40-80] in controls ($p = 0.03$). This was consistent with the superior neutralization of wild-type virus
291 observed in PLWH at this timepoint (**Figure 2**). Neutralization of wild-type and Omicron viruses
292 correlated significantly with their respective ACE2 displacement activities (all $p < 0.0001$, **Supplemental**
293 **Figure 2**).

294 **DISCUSSION**

295 Our study confirms that antibody concentrations and neutralizing activities naturally decline
296 following two-dose COVID-19 vaccination [31, 43]. Nevertheless, we found no evidence that PLWH
297 receiving suppressive antiretroviral therapy exhibited lower antibody concentrations at any time point up
298 to six months following two-dose vaccination, nor did they exhibit faster rates of antibody decline during
299 this period compared to controls, after accounting for sociodemographic, health- and vaccine-related
300 factors. Similarly we found no evidence that PLWH exhibited poorer neutralization at any time point after
301 two doses compared to controls. These observations are consistent with data from PLWH participants of
302 the original ChAdOx1 trial, which reported no significant difference in immune response decline in
303 PLWH compared to controls following two vaccine doses [37].

304 Our results also showed that a third vaccine dose boosted binding antibody concentrations and
305 function to significantly higher levels than those observed after two doses. After three doses, antibody
306 concentrations in PLWH were equivalent to controls, while neutralization activities were slightly higher.
307 The higher neutralization is attributable to PLWH more frequently receiving mRNA-1273 (vs.
308 BNT162b2) third doses, which was the strongest correlate of higher neutralization after three-dose
309 vaccination (**Supplemental Table 3**). In fact, the majority of PLWH were eligible for full (100 mcg)
310 mRNA-1273 third doses, which likely boosted responses still further, though we were not able to confirm
311 this due to incomplete dose information. Consistent with accumulating evidence [44-47], antibody
312 responses against Omicron were universally weaker than against wild-type after two and three vaccine
313 doses, though the third dose significantly boosted anti-Omicron responses. Indeed, post-third-dose anti-
314 Omicron responses in PLWH were equivalent to or higher than controls, again possibly attributable to a
315 higher proportion of PLWH receiving (full) mRNA-1273 third doses.

316 Our study has several limitations. Our results may not be generalizable to PLWH who are not
317 receiving antiretroviral therapy, who have multiple co-morbidities or who have CD4+ T-cell counts <200
318 cells/mm³. We found no evidence that a low nadir CD4+ T-cell count negatively influenced COVID-19
319 vaccine response however, indicating that prior low CD4 T+ cell counts will not necessarily compromise
320 immune responses to COVID-19 vaccines presently. We did not investigate T-cell responses, which may
321 play critical protective roles, particularly against variants [48, 49]. Individuals ≥70 years old and PLWH
322 meeting priority criteria were eligible for full mRNA-1273 third doses, but we could not directly assess
323 mRNA-1273 dose-related effects on immune responses due to incomplete dosing information. Finally,
324 while immune correlates of vaccine-mediated protection are being elucidated for SARS-CoV-2 [50], the
325 implications of our results on individual-level protection from infection and disease remain uncertain,
326 particularly in the context of Omicron.

327 In conclusion, adult PLWH with well-controlled viral loads and preserved CD4+ T-cell counts
328 mount strong and functional antibody responses to two and three COVID-19 vaccine doses, including to
329 Omicron, though it will be important to monitor these responses over time. Studies of PLWH who are not
330 receiving antiretroviral treatment or who have low CD4+ T-cell counts are also needed.

331 **ACKNOWLEDGEMENTS**

332 We thank the leadership and staff of Providence Health Care for their support of this study. We
333 thank the phlebotomists and laboratory staff at St. Paul's Hospital, the BC Centre for Excellence in
334 HIV/AIDS and Simon Fraser University for assistance. Above all, we thank the participants, without
335 whom this study would not have been possible.

336 This work was supported by funding from Genome BC, the Michael Smith Foundation for Health
337 Research, and the BCCDC Foundation for Public Health through a rapid SARS-CoV-2 vaccine research
338 initiative in BC award (VAC-009 to ZLB, MAB). It was also supported by the Public Health Agency of
339 Canada (PHAC) through two COVID-19 Immunology Task Force (CITF) COVID-19 Awards (to ZLB,
340 MGR, MAB and to CTC, CC, AHA), the Canada Foundation for Innovation through Exceptional
341 Opportunities Fund – COVID-19 awards (to CJB, CFL, MAB, MN, MLD, RP, ZLB), a British Columbia
342 Ministry of Health–Providence Health Care Research Institute COVID-19 Research Priorities Grant (to
343 CJB and CFL), the CIHR Canadian HIV Trials Network (CTN) (to AHA) and the National Institute of
344 Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). MLD and ZLB
345 hold Scholar Awards from the Michael Smith Foundation for Health Research. FA was supported by an
346 SFU Undergraduate Research Award. GU and FHO are supported by Ph.D. fellowships from the Sub-
347 Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative
348 [grant # DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African
349 Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and
350 supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD
351 Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. The
352 views expressed in this publication are those of the authors and not necessarily those of PHAC, CITF,
353 AAS, NEPAD Agency, Wellcome Trust, the Canadian or UK governments or other funders.

354 **FIGURE LEGENDS**

355 **Figure 1. Concentrations of total binding antibodies in serum to spike RBD following two and three**

356 **COVID-19 vaccine doses. Panel A:** Binding antibody responses to the SARS-CoV-2 spike RBD in serum

357 at one, three and six months following the second dose, and one month following the third vaccine dose,

358 in PLWH (orange) and controls (blue) who were COVID-19 naive at the studied time point, as well as

359 individuals who had recovered from COVID-19 at the studied time point (COVID group, black).

360 Participants who experienced a post-vaccination infection were relocated from their original group into the

361 COVID group at their first post-infection study visit, where they are denoted by a red symbol. Participant

362 Ns are shown at the bottom of the plot. The thick horizontal red bar represents the median; thinner

363 horizontal red bars represent the IQR. P-values were computed using the Mann-Whitney U-test (for

364 comparisons between groups) or the Wilcoxon matched pairs test (for comparisons across time points

365 within a group) and are uncorrected for multiple comparisons. ULOQ: upper limit of quantification;

366 LLOD: lower limit of detection. *Panel B:* Temporal declines in serum binding antibody responses to

367 spike-RBD following two vaccine doses in PLWH (orange) and controls (blue) who remained COVID-19

368 naive during this period. Only participants with a complete longitudinal data series with no values above

369 the ULOQ are shown. *Panel C:* Binding antibody half-lives following two COVID-19 vaccine doses,

370 calculated by fitting an exponential curve to the data shown in panel B. Ns are indicated at the bottom of

371 the plot. Red bars and whiskers represent the median and IQR. P-value computed using the Mann-

372 Whitney U-test.

373

374 **Figure 2. Live virus neutralization activities following two and three COVID-19 vaccine doses. Viral**

375 neutralization activity in plasma at one, three and six months following the second dose, and one month

376 following the third vaccine dose, in PLWH (orange) and controls (blue) who were COVID-19 naive at the

377 studied time point, as well as individuals who had recovered from COVID-19 at the studied time point
378 (COVID group, black). Plasma neutralization was defined as the reciprocal of the highest plasma dilution
379 at which vial cytopathic effect was prevented in all triplicate assay wells. Plasma samples showing
380 neutralization in fewer than three wells at the lowest plasma dilution of 1/20 were coded as having a
381 reciprocal dilution of 10, corresponding to the lower limit of quantification (LLOQ) in this assay. The
382 highest dilution tested was 1/2560, which corresponds to the upper limit of quantification (ULOQ).
383 Participants who experienced a post-vaccination infection were relocated from their original group into the
384 COVID19 group at their first post-infection study visit, where they are denoted by a red symbol.
385 Participant Ns are shown at the bottom of the plot. The thick horizontal red bar represents the median;
386 thinner horizontal red bars represent the IQR. P-values were computed using the Mann-Whitney U-test
387 (for comparisons between groups) or the Wilcoxon matched pairs test (for comparisons across time points
388 within a group) and are uncorrected for multiple comparisons.

389

390 **Figure 3: Anti-Omicron IgG binding and ACE2 displacement activities one month after the second**
391 **and third COVID-19 vaccine doses.** *Panel A:* Binding IgG responses in plasma to the wild-type (WT)
392 and Omicron (OM) spike-RBD (S-RBD), measured using the Meso Scale Diagnostics V-Plex assay, in
393 PLWH (orange) and controls (blue) who remained COVID-19 naive throughout the study. Participant Ns
394 are shown at the bottom of the plot. Thick horizontal red bar represents the median; thinner horizontal red
395 bars represent the IQR. P-values were computed using the Wilcoxon matched pairs test (for all within-
396 group comparisons) or the Mann-Whitney U-test (for between-group comparisons) and are uncorrected
397 for multiple comparisons. *Panel B:* same as A, but for ACE2 displacement activity, measured using the V-
398 plex SARS-CoV-2 (ACE2) assay, where results are reported in terms of % ACE2 displacement.
399

400

401 **Figure 4: Anti-Omicron neutralization activities one month after the second and third COVID-19**
402 **vaccine doses.** Neutralization activities, reported as the reciprocal of the highest plasma dilution at which
403 neutralization was observed in all triplicate assay wells, against the wild-type (WT) and Omicron (OM)
404 virus isolates a subset of PLWH (orange) and controls (blue) who remained COVID-19 naive throughout
405 the study. Participant Ns are shown at the bottom of the plot. Thick horizontal red bar represents the
406 median; thinner horizontal red bars represent the IQR. P-values were computed using the Wilcoxon
407 matched pairs test (for within-group comparisons) or the Mann-Whitney U-test (for between-group
408 comparisons) and are uncorrected for multiple comparisons.

409

410 **SUPPLEMENTAL FIGURES**

411 **Supplemental Figure 1: Relationships between most recent and nadir CD4+ T-cell counts and**
412 **humoral responses following two and three vaccine doses.** Relationships were assessed using
413 Spearman's correlation. Measurements against wild-type SARS-CoV-2 at six months post-second-dose
414 are indicated by red symbols; measurements against wild-type SARS-CoV-2 at one month post-third-dose
415 are indicated by blue symbols; measurements against Omicron at one month post-third-dose are indicated
416 by open symbols. Analyses are restricted to COVID-19-naive PLWH. LLOQ: Lower limit of
417 quantification; ULOQ: Upper limit of quantification.

418

419 **Supplemental Figure 2: Relationships between ACE2 % displacement and viral neutralization**
420 **activity against wild-type and Omicron after two and three COVID-19 vaccine doses.** Relationships
421 were assessed using Spearman's correlation. Measurements against wild-type SARS-CoV-2 are indicated
422 by blue symbols; measurements against Omicron are indicated by open symbols. Reported Ns reflect all

423 measurements completed on all study participants (PLWH and controls) regardless of prior COVID-19
424 (while Figures 3 and 4 report only results from COVID-19-naive participants). LLOQ: Lower limit of
425 quantification.

426 **REFERENCES**

- 427 1. Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of COVID-19 related hospitalization among
428 people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective
429 observational study. *Clin Infect Dis* **2020**.
- 430 2. Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study
431 from the Western Cape Province, South Africa. *Clin Infect Dis* **2020**.
- 432 3. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 Outcomes Among Persons Living With or
433 Without Diagnosed HIV Infection in New York State. *JAMA network open* **2021**; 4:e2037069.
- 434 4. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based
435 cohort analysis of UK primary care data and linked national death registrations within the
436 OpenSAFELY platform. *Lancet HIV* **2021**; 8:e24-e32.
- 437 5. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase
438 3 vaccine candidates. *Lancet* **2020**; 396:1595-606.
- 439 6. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
440 Vaccine. *N Engl J Med* **2021**; 384:403-16.
- 441 7. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
442 Vaccine. *N Engl J Med* **2020**; 383:2603-15.
- 443 8. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of Seropositivity Following BNT162b2
444 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
445 *JAMA oncology* **2021**; 7:1133-40.
- 446 9. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following
447 SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med*
448 **2021**.
- 449 10. Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines
450 against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an
451 investigator-initiated, single-centre, open-label study. *The Lancet Rheumatology* **2021**.
- 452 11. Deepak P, Kim W, Paley MA, et al. Effect of Immunosuppression on the Immunogenicity of mRNA
453 Vaccines to SARS-CoV-2 : A Prospective Cohort Study. *Ann Intern Med* **2021**.
- 454 12. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2
455 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *Am J*
456 *Transplant* **2021**; 21:2719-26.

- 457 13. Plana M, García F, Gallart T, et al. Immunological benefits of antiretroviral therapy in very early
458 stages of asymptomatic chronic HIV-1 infection. *Aids* **2000**; 14:1921-33.
- 459 14. Kaufmann GR, Zaunders JJ, Cunningham P, et al. Rapid restoration of CD4 T cell subsets in subjects
460 receiving antiretroviral therapy during primary HIV-1 infection. *Aids* **2000**; 14:2643-51.
- 461 15. Bart PA, Rizzardi GP, Tambussi G, et al. Immunological and virological responses in HIV-1-infected
462 adults at early stage of established infection treated with highly active antiretroviral therapy. *Aids*
463 **2000**; 14:1887-97.
- 464 16. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic
465 HIV Infection. *N Engl J Med* **2015**; 373:795-807.
- 466 17. El Chaer F, El Sahly HM. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine
467 Efficacy and Immunogenicity. *Am J Med* **2019**; 132:437-46.
- 468 18. Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to
469 vaccination in HIV-infected patients: a systematic review and meta-analysis. *Clin Infect Dis* **2014**;
470 58:1130-9.
- 471 19. Geretti AM, Doyle T. Immunization for HIV-positive individuals. *Curr Opin Infect Dis* **2010**; 23:32-8.
- 472 20. Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222)
473 vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
474 *Lancet HIV* **2021**; 8:e474-e85.
- 475 21. Madhi SA, Koen AL, Izu A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222)
476 vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim
477 analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. *Lancet HIV* **2021**;
478 8:e568-e80.
- 479 22. Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA
480 COVID-19 vaccine in people living with HIV-1. *Clin Microbiol Infect* **2021**.
- 481 23. Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA Vaccine Elicits Robust
482 Humoral and Cellular Immune Responses in People Living with HIV. *Clin Infect Dis* **2021**.
- 483 24. Ruddy JA, Boyarsky BJ, Bailey JR, et al. Safety and antibody response to two-dose SARS-CoV-2
484 messenger RNA vaccination in persons with HIV. *Aids* **2021**.
- 485 25. Noe S, Ochana N, Wiese C, et al. Humoral response to SARS-CoV-2 vaccines in people living with
486 HIV. *Infection* **2021**:1-7.

- 487 26. Balcells ME, Le Corre N, Durán J, et al. Reduced immune response to inactivated SARS-CoV-2
488 vaccine in a cohort of immunocompromised patients in Chile. *Clin Infect Dis* **2022**.
- 489 27. Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses across
490 a broad spectrum of immunocompromising conditions: the COVICS study. *Clin Infect Dis* **2022**.
- 491 28. Brumme ZL, Mwimanzi F, Lapointe HR, et al. Humoral immune responses to COVID-19 vaccination
492 in people living with HIV receiving suppressive antiretroviral therapy. *NPJ vaccines* **2022**; 7:28.
- 493 29. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to time-
494 from-vaccine. *Nat Commun* **2021**; 12:6379.
- 495 30. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel.
496 *N Engl J Med* **2021**; 385:e85.
- 497 31. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
498 Vaccine over 6 Months. *N Engl J Med* **2021**; 385:e84.
- 499 32. Doria-Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2
500 Omicron Escape from Neutralizing Antibodies. *medRxiv* **2021**.
- 501 33. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
502 induce neutralizing immunity against SARS-CoV-2 Omicron variant. *medRxiv* **2021**.
- 503 34. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2
504 Omicron variant. *medRxiv* **2021**.
- 505 35. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against
506 Omicron Variant in South Africa. *N Engl J Med* **2021**.
- 507 36. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of
508 Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. *medRxiv* **2021**.
- 509 37. Ogbe A, Pace M, Bittaye M, et al. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people
510 living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses.
511 *medRxiv* **2021**:2021.09.28.21264207.
- 512 38. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-
513 19 in Israel. *N Engl J Med* **2021**; 385:1393-400.
- 514 39. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine
515 boosters in healthy adults: an interim analysis. *Nat Med* **2021**; 27:2025-31.
- 516 40. Falsey AR, Frencck RW, Jr., Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine
517 Dose 3. *N Engl J Med* **2021**; 385:1627-9.

- 518 41. Mattiuzzo G, Bentley EM, Hasall M, et al. Establishment of the WHO International Standard and
519 Reference Panel for anti-SARS-CoV-2 antibody. In:
520 WHO_Expert_Committee_on_Biological_Standardization, ed. Vol. WHO/BS/2020.2402. Geneva:
521 World_Health_Organization, **2020**.
- 522 42. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on
523 antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **2020**;
524 38:1073-8.
- 525 43. Notarte KI, Guerrero-Arguero I, Velasco JV, et al. Characterization of the significant decline in
526 humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
527 *J Med Virol* **2022**.
- 528 44. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against
529 Omicron Variant in South Africa. *N Engl J Med* **2022**; 386:494-6.
- 530 45. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2
531 neutralization. *Nature* **2022**; 602:654-6.
- 532 46. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
533 induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* **2022**; 185:457-66.e4.
- 534 47. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody
535 neutralization. *Nature* **2022**; 602:671-5.
- 536 48. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize
537 Omicron. *Nature* **2022**.
- 538 49. Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-
539 CoV-2 Omicron. *Nature* **2022**.
- 540 50. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
541 SARS-CoV-2 infection. *Nat Med* **2021**; 27:2032-40.
- 542

Table 1: Participant characteristics

Characteristic	PLWH (n=99)	Controls (n=152)
HIV-related variables		
Receiving antiretroviral therapy, n (%)	99 (100%)	-
Most recent plasma viral load, copies HIV RNA/mL, median [IQR]	<50 [<50 - <50]	-
Most recent CD4+ T-cell count in cells/mm ³ , median [IQR]	715 [545-943]	-
Nadir CD4+ T-cell count in cells/mm ³ , median [IQR]	280 [123-490]	-
Sociodemographic and health variables		
Age in years, median [IQR]	54 [40-61]	47 [35-70]
Male sex at birth, n (%)	87 (88%)	50 (33%)
Ethnicity, n (%)		
white/Caucasian	69 (69%)	78 (51%)
Black	5 (5%)	1 (0.7%)
Asian	10 (10%)	59 (38%)
Latin American	8 (8%)	4 (2.6%)
Middle Eastern/Arab	3 (3%)	0 (0%)
Mixed ethnicity	3 (3%)	8 (5.3%)
Not disclosed	1 (1%)	2 (1.3%)
Number of chronic health conditions, median [IQR]	0 [0-1]	0 [0-1]
Hypertension, n (%)	15 (15%)	22 (14.5%)
Diabetes, n (%)	6 (6%)	6 (3.9%)
Asthma, n (%)	7 (7%)	15 (9.9%)
Obesity, n (%)	15 (15%)	14 (9.2%)
Chronic lung disease, n (%)	4 (4%)	3 (2%)
Chronic liver disease, n (%)	4 (4%)	1 (0.7%)
Chronic kidney disease, n (%)	1 (1%)	1 (0.7%)
Chronic heart disease, n (%)	1 (1%)	4 (2.6%)
Chronic blood disease, n (%)	1 (1%)	2 (1.3%)
Cancer, n (%)	4 (4%)	4 (2.6%)
Immunosuppression, n (%)	3 (3%)	0 (0%)
At least one of the above, n (%)	45 (45%)	50 (33%)
COVID-19 status		
COVID-19 convalescent (anti-N Ab+) at study entry, n (%)	8 (8%)	15 (10%)
COVID-19 post-vaccination	18 (18%)	13 (9%)
Vaccine details		
Initial two-dose regimen		
mRNA - mRNA	82 (82%)	148 (97%)
ChAdOx1 - mRNA (heterologous)	8 (8%)	3 (2%)
ChAdOx1 - ChAdOx1	8 (8%)	1 (0.7%)
ChAdOx1 - not disclosed	1 (1%)	-
Time between first and second doses in days, median [IQR]	58 [53-67]	89 [65-98]
Third dose		
BNT162b2	23 of 80 (29%)	55 of 134 (41%)
mRNA-1273	56 of 80 (70%)	79 of 134 (59%)
Unknown	1 of 80 (1%)	-
Time between second and third doses in days, median [IQR]	183 [143-191]	198 [173-216]
Specimen collection		
Specimen one month after second dose, n (%)	97 (97%)	151 (99%)
Day of collection one month after second dose, median [IQR]	30 [29-30]	30 [29-32]
Specimen three months after second dose, n (%)	96 (96%)	148 (97%)
Day of collection three months after second dose, median [IQR]	90 [90-91]	90 [89-91]
Specimen six months after second dose, n (%)	62 (62%)	136 (89%)
Day of collection six months after second dose, median [IQR]	180 [177-182]	180 [178-182]
Specimen one month after third dose, n (%)	80 (80%)	134 (88%)
Day of collection one month after third dose, median [IQR]	30 [30-32]	30 [29-32]

Table 2: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on antibody concentrations 6 months after the second dose, and antibody half-lives following the second dose

Variable ^a	Log ₁₀ antibody concentration 6 mo after 2nd dose ^b			Antibody half-lives after the 2nd dose ^c		
	Estimate	95% CI	p-value	Estimate	95% CI	p-value
HIV infection	-0.036	-0.19 to 0.11	0.64	6.33	-19.92 to 32.59	0.63
Age (per year)	0.000019	-0.0043 to 0.0043	0.99	0.53	-0.12 to 1.17	0.11
Male sex	-0.059	-0.19 to 0.072	0.37	9.36	-12.83 to 31.54	0.41
White ethnicity	-0.0078	-0.13 to 0.11	0.90	-7.03	-26.97 to 12.90	0.49
# Chronic conditions (per additional)	-0.028	-0.11 to 0.056	0.51	-7.58	-21.67 to 6.51	0.29
Dual ChAdOx1 as initial regimen	-0.94	-1.39 to -0.49	<0.0001	2.84	-76.02 to 81.70	0.94
Interval between first and second doses (per day)	0.0024	-0.00036 to 0.0052	0.087	-0.17	-0.63 to 0.29	0.47
Days since second dose	0.012	0.0033 to 0.020	0.0067	-	-	-
Prior COVID-19	0.50	0.35 to 0.65	<0.0001	-	-	-

^a Dashes indicate variables not included in the model

^b quantified using the Roche Elecsys anti-S assay

^c Calculated from all participants with a complete longitudinal data series following the second dose with no values above the ULOQ, and no evidence of prior COVID-19

Table 3: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on antibody responses to Omicron after three COVID-19 vaccine doses

Variable ^a	anti-Omicron log ₁₀ Binding IgG ^b			anti-Omicron ACE2 % displacement ^b		
	Estimate	95% CI	p-value	Estimate	95% CI	p-value
HIV infection	0.36	0.14 to 0.58	0.0017	3.49	-8.48 to 15.47	0.57
Age (per year)	-0.0030	-0.0078 to 0.0018	0.22	0.21	-0.056 to 0.47	0.12
Male sex	-0.19	-0.36 to -0.017	0.032	-10.26	-19.58 to -0.94	0.031
White ethnicity	0.045	-0.10 to 0.19	0.55	2.05	-6.00 to 10.09	0.62
# Chronic conditions (per additional)	0.0032	-0.083 to 0.090	0.94	-1.27	-5.99 to 3.45	0.60
Dual ChAdOx1 as initial regimen (vs mixed or mRNA)	-0.14	-0.48 to 0.20	0.42	-6.80	-25.39 to 11.80	0.47
mRNA-1273 as third dose (vs BNT162b2)	0.15	0.0074 to 0.30	0.039	5.16	-2.80 to 13.12	0.20
Interval between 1st and 2nd dose (per day)	0.0022	-0.0016 to 0.0059	0.26	-0.044	-0.25 to 0.16	0.67
Interval between 2nd and 3rd dose (per day)	0.0036	0.0012 to 0.0060	0.0039	0.065	-0.067 to 0.20	0.33
Days since 3rd dose	-0.0073	-0.022 to 0.0080	0.35	0.11	-0.72 to 0.94	0.80

^a Analysis was restricted to participants with no evidence of prior COVID-19

^b Both immunogenicity measures were quantified in serum using the Meso Scale Diagnostics V-Plex assay (panel 22) which features wild-type and Omicron S-RBD.








a**b****c**

Figure 2







Supplemental Table 1: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on immunogenicity measures one and three months following the second vaccine dose

Immunogenicity outcome	Variable	Time point					
		1 month after 2nd dose			3 months after 2nd dose		
		Estimate	95% CI	p-value	Estimate	95% CI	p-value
Log₁₀ anti-RBD Abs^a	HIV infection	-0.017	-0.18 to 0.14	0.83	-0.13	-0.27 to 0.019	0.088
	Age (per year)	-0.0057	-0.0098 to -0.0017	0.0053	-0.0035	-0.0072 to 0.000079	0.055
	Male sex	-0.016	-0.16 to 0.13	0.82	0.028	-0.10 to 0.16	0.68
	White ethnicity	0.053	-0.078 to 0.18	0.43	0.048	-0.069 to 0.17	0.42
	# Chronic conditions (per additional)	-0.11	-0.19 to -0.030	0.0072	-0.086	-0.16 to -0.012	0.022
	Dual ChAdOx1 as initial regimen	-0.63	-0.97 to -0.29	0.0003	-0.70	-1.00 to -0.40	<0.0001
	Interval btw 1st and 2nd doses (per day)	0.0036	0.00039 to 0.0069	0.028	0.0037	0.00085 to 0.0066	0.011
	Days since second dose	-0.0018	-0.024 to 0.020	0.87	0.0061	-0.010 to 0.022	0.46
	Prior COVID-19	0.063	-0.13 to 0.26	0.53	0.14	-0.030 to 0.31	0.10
Viral neutralization^b	HIV infection	0.20	-0.47 to 0.86	0.56	-0.063	-0.74 to 0.62	0.86
	Age (per year)	-0.018	-0.030 to -0.0050	0.0064	-0.012	-0.025 to 0.00051	0.059
	Male sex	-0.39	-0.84 to 0.055	0.086	-0.12	-0.59 to 0.34	0.60
	White ethnicity	-0.21	-0.61 to 0.18	0.29	-0.19	-0.60 to 0.21	0.36
	# Chronic conditions (per additional)	-0.29	-0.53 to -0.041	0.022	-0.15	-0.41 to 0.10	0.23
	Dual ChAdOx1 as initial regimen	-1.39	-2.41 to -0.37	0.0077	-1.57	-2.60 to -0.53	0.0032
	Interval btw 1st and 2nd doses (per day)	0.0073	-0.0038 to 0.018	0.2	0.00067	-0.010 to 0.012	0.91
	Days since second dose	-0.0061	-0.073 to 0.060	0.86	-0.029	-0.084 to 0.027	0.31
	EDTA as anticoagulant ^c	0.85	0.091 to 1.61	0.028	0.58	-0.20 to 1.35	0.14
Prior COVID-19	1.15	0.56 to 1.75	0.0002	1.65	1.06 to 2.24	<0.0001	

^aquantified using the Roche Elecsys anti-S assay

^bfor viral neutralization, reciprocal plasma dilutions were log₂ transformed prior to multivariable analysis.

^cNeutralization assays were performed using plasma, so the analysis also corrects for the anticoagulant used, with ACD as the reference category.

Analyses of anti-RBD concentration do not correct for this variable because this assay was performed on serum collected in the same tube type.

Supplemental Table 2: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables and detectable viral neutralization activity six months following the second vaccine dose

Immunogenicity outcome	Variable	Odds Ratio	95% CI	p-value
Detectable viral neut. 6 months after 2nd dose^a	HIV infection	0.51	0.12 to 1.77	0.32
	Age (per year)	0.98	0.96 to 1.01	0.22
	Male sex	0.68	0.29 to 1.50	0.35
	White ethnicity	0.88	0.44 to 1.78	0.73
	# Chronic conditions (per additional)	1.00	0.61 to 1.63	1.00
	Dual ChAdOx1 as initial regimen	0.19	0.0079 to 2.36	0.21
	Interval btw 1st and 2nd doses (per day)	1.01	0.99 to 1.03	0.14
	Days since second dose	1.03	0.98 to 1.09	0.24
	EDTA as anticoagulant ^b	9.31	2.41 to 44.62	0.0023
	Prior COVID-19	4.57	1.74 to 13.99	0.0037

^a Results are presented as the adjusted Odds Ratios and 95% CI of detectable viral neutralization activity at this time point, calculated using multivariable logistic regression.








^b Neutralization assays were performed using plasma, so the analysis also corrects for the anticoagulant used, with ACD as the reference category.

Supplemental Table 3: Multivariable analysis of the relationship between sociodemographic, health and vaccine-related variables and viral neutralization activity one month following the third vaccine dose

Immunogenicity outcome	Variable	Estimate	95% CI	p-value
Viral neut. (log₂) 1 mo after 3rd dose^a	HIV infection	0.58	-0.22 to 1.37	0.15
	Age (per year)	-0.00068	-0.017 to 0.016	0.94
	Male sex	-0.047	-0.61 to 0.51	0.87
	White ethnicity	-0.27	-0.74 to 0.20	0.27
	# Chronic conditions (per additional)	-0.067	-0.35 to 0.21	0.64
	Dual ChAdOx1 as initial regimen	0.96	-0.18 to 2.10	0.099
	mRNA-1273 as third dose (vs. BNT162b2)	0.78	0.32 to 1.23	0.0009
	Interval between 1st and 2nd doses (per day)	-0.00095	-0.015 to 0.013	0.89
	Interval between 2nd and 3rd doses (per day)	0.0016	-0.0066 to 0.0097	0.71
	Days since 3rd dose (per day)	-0.016	-0.065 to 0.034	0.53
	EDTA as anticoagulant ^b	0.28	-0.68 to 1.25	0.56
	Prior COVID-19	0.98	0.39 to 1.57	0.0013

^afor viral neutralization, reciprocal plasma dilutions were log₂ transformed prior to multivariable analysis.

^bNeutralization assays were performed using plasma, so the analysis also corrects for the anticoagulant used, with ACD as the reference category.

a**b****c****d****e****f****g****h**